Kim N. Chi is a Medical Oncologist and the Chief Medical Officer and Executive Vice President for BC Cancer, which provides a comprehensive cancer control program for the people of British Columbia, Canada. He is also a Professor of Medicine at the University of British Columbia, as well as a Senior Research Scientist at the Vancouver Prostate Centre. He is the past-Chair of the Genitourinary Disease Site Committee for the Canadian Cancer Trials Group (CCTG). His research is in the area of genitourinary cancers with a focus on prostate cancer and investigational new drugs. This includes outcomes research, biomarkers, and phase I-III clinical trials. He has received peer-reviewed grant funding from the Canada Institutes of Health Research (CIHR), the Canadian Cancer Society (CCS), the US Department of Defense, Movember, the Prostate Cancer Foundation (US), and Prostate Cancer Canada.

Steven M. Yip is a Staff Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta. He is the Precision Oncology & Experimental Therapeutics (POET) Medical Oncology Lead, the Southern Alberta GU Tumour Group Chair, and a Clinical Assistant Professor of Medicine at the University of Calgary. He has an academic focus on translational research, PSMA PET/CT imaging, and novel radiopharmaceutical drug development in advanced prostate cancer. He completed his medical oncology clinical and translational research genitourinary fellowship, under the supervision of Dr. Kim Chi at BC Cancer. He received his MD at the University of Alberta and trained at the University of British Columbia and the University of Calgary. He has a Master of Science in Health Research Methodology from McMaster University.

Glenn Bauman is a Radiation Oncologist, specializing in Genitourinary and Central Nervous System Malignancies, at the London Regional Cancer Program. He is also the Professor and Chair of the Department of Oncology at the Schulich School of Medicine and Dentistry, University of Western Ontario in London, Ontario, and is an Associate Scientist at Lawson Health Research Institute. He received both his undergraduate and medical degrees from the University of Western Ontario, where he also completed his residency in Radiation Oncology. A clinical fellowship in Radiation Oncology in the area of adult and pediatric brain tumor treatment was completed at the University of California at San Francisco. His primary areas of clinical practice are in genitourinary and central nervous system tumors and his areas of research interest are multi-modality image-guided radiotherapy and cancer imaging.

N/A

Urban Emmenegger is a Medical Oncologist, who in 2008 was appointed as a Clinician Scientist at the Odette Cancer Centre (Division of Medical Oncology) and the Sunnybrook Research Institute (Biological Sciences). He is an Assistant Professor in the Department of Medicine, and an Associate Member of the Institute of Medical Science, both at the University of Toronto.He obtained his medical degree from the University of Bern, Switzerland, in 1992. Following training in Internal Medicine and Medical Oncology, in 2001 he joined the Laboratory of Dr. Robert S. Kerbel (Sunnybrook Research Institute) to undertake postdoctoral training in tumor biology, with special emphasis on tumor angiogenesis and metronomic chemotherapy. He also completed a fellowship in Medical Oncology at the University of Toronto in 2008. He is specialized in the systemic treatment of advanced prostate cancer. Aside from clinical trial activities, he is interested in characterizing relevant drug–drug interactions between novel prostate cancer medications and medications frequently used by the typically elderly prostate cancer patient with numerous co-morbidities.

Christian K. Kollmannsberger is a Staff Medical Oncologist and Head of the Department of Medical Oncology at BC Cancer, Vancouver Cancer Centre, as well as a Clinical Professor in the Division of Medical Oncology at the University of British Columbia. He graduated from the Technical University in Munich, Germany, and received his clinical training in Internal Medicine, Hematology, and Medical Oncology, mainly at the University of Tuebingen, Germany. He has a full-time clinical practice focusing on genitourinary cancers and new drug development. He currently is the Chair of the BC Genitourinary Tumor Group as well as the GU Clinical Trials Unit at BC Cancer—Vancouver Center. His research is focussed on genitourinary malignancies with a special interest in testicular and renal cell cancer. Nationally and internationally, he has contributed to numerous trials in the field of renal cell carcinoma and testicular cancer. He has authored or co-authored more than 280 publications in peer-reviewed journals. He has repeatedly served as faculty for the Annual Meeting of the American Society of Clinical Oncology (ASCO) and the Annual Meeting of the European Society of Medical Oncology (ESMO), and as faculty and program chair for the ASCO Genitourinary Cancers Symposium.

Patrick Martineau is a Nuclear Medicine Specialist and Researcher in the Department of Nuclear Medicine at the Health Sciences Centre, as well as an Assistant Professor in the Department of Nuclear Medicine at the University of Manitoba, Canada. He works at the BC Cancer Agency in Vancouver, Canada. He obtained his MDCM, PhD, and MSc from McGill University and subsequently completed his residency training in Nuclear Medicine and Radiology at The Ottawa Hospital (TOH) and the University of Ottawa Heart Institute (UOHI), Canada. His research focuses on non-invasive cardiovascular imaging, particularly hybrid imaging with PET/CT and SPECT/CT. His interests include the development of new imaging techniques and the development and validation of new clinical applications, as well as clinical trials.

Tamim Niazi received his Doctor of Medicine and Master of Surgery (MDCN) designation from McGill University in 2001. He completed his internship and residency at the McGill University Health Centre. In 2006–2007, he was the Astra Zeneca Clinical Trials Fellow with the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). He is currently an Assistant Professor of the Department of Oncology at McGill. His clinical expertise makes him a sought-after lecturer on both the academic and medical fronts. His specialties include GU malignancies (prostate, bladder, testicle, etc.), GI malignancies (stomach, pancreas, rectum, anal canal), and gynecological malignancies. He is a full member of the McGill Centre for Translational Research in Cancer and an investigator at the Lady Davis Institute for Medical Research.

Frédéric Pouliot is a renowned Clinical Uro-Oncologist and Associate Professor in the Department of Surgery at Laval University. He obtained a Doctorate in Medicine (Md) and a Doctorate in Physiology-Endocrinology (PhD) at Laval University. He participates in Canadian and international research projects, recognized by various funding organizations such as the Fond de la Recherche en Santé du Québec, the Cancer Research Society, Oncopole, Prostate Cancer Canada, and Movember. He is the recipient of career scholarships from the Senior Clinical Research Fellow program of the Fonds de la recherche en santé du Québec as well as the Rising Star Award awarded by Prostate Cancer Canada and Movember. His expertise in genitourinary cancers has been recognized by invitations to serve as a member of the US National Cancer Institute’s Prostate Cancer Working Group, the Genitourinary Trials Development Group of the Canadian Clinical Trial Group, and the Executive Committee of the Canadian Urological Association.

Ricardo Rendon obtained his MD and completed his residency at Universidad Javeriana. He subsequently completed a clinical and research UroOncology Fellowship at the University of Toronto, Canada, and a Masters in Community Health Clinical Epidemiology. In 2001, he joined Dalhousie University in Halifax, Canada, where he is a Professor in the Department of Urology and the Director of Research and Clinical Trials. He is the Chair of the Genito-Urinary Cancer Site Team, Nova Scotia Health Authority Cancer Program. He is currently the Vice-President of Education of the Canadian Urological Association and Chair of the Canadian Urologic Oncology Group. While his clinical practice focusses on all areas of urologic oncology, his research focusses on renal cell carcinoma, advanced prostate cancer, and urothelial cell carcinoma.

Sebastien J. Hotte is currently an Associate Professor in the Department of Oncology of McMaster University and is a Staff Oncologist at the Juravinski Cancer Centre. One of his main research interests is in Developmental Therapeutics and Phase I trials with clinical research interests in genito-urinary malignancies and is active in the field of translational research. He is the Head of the Phase I Research Program and Chair of the Head and Neck Disease Site Group. Provincially, he is the Co-Chair of the Genitourinary disease site group of the Program for Evidence-Based Care (PEBC) of Cancer Care Ontario. His translational research areas of interest are the molecular biology of human cancer drug development and the discovery of biomarkers of toxicity and efficacy for novel targeted agents. He is an Associate Scientist of the Escarpment Cancer Research Institute and the co-chair of the Cancer Care Ontario Program for Evidence-Based Care GU disease site group.

David T. Laidley is an Assistant Professor at the Department of Medical Imaging—Nuclear Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario. He received a Nuclear Medicine Residency at the University of Western Ontario. He won the Fellowship at the McGill University. He is a member of the Society of Nuclear Medicine and Molecular Imaging, the American Association of Nuclear Cardiology, the Canadian Association of Nuclear Medicine, and the Ontario Association of Nuclear Medicine. He was a Clinical Investigator for An Open Label Phase II, Registry Study of Luletium-177 (DOTA.Tyrl Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours in 2014. He won the Dr. Bruce A. Fraser Award in 2007 and the Alfred Burness Award in 2003.

Fred Saad, MD FRCS, is Professor and Chairman of Urology, Director of G-U Oncology, and holds the Raymond Garneau Chair in Prostate Cancer Research at the University of Montreal Hospital Centre. He is the Past President of the Canadian Urologic Association, NCIC G-U Group, and Canadian Urologic Oncology Group. He sits on several prestigious editorial boards including the Lancet Oncology, JAMA Oncology, and Nature Urology. He sits on several steering committees of international clinical trials and has played a leadership role in many of the practice-changing clinical trials in advanced prostate cancer over the past 25 years. He has published more than 600 peer-reviewed articles and, with an h-factor of 123 and more than 75,000 citations, he is listed as one of the world’s most cited scientists. His research interests include novel therapeutics in prostate cancer and molecular prognostic markers and he has received more than CAD 40 million in research grants. He has received numerous awards and in 2018 was named a Knight of The National Order of Quebec, the highest honor given by the Quebec government.